Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer
ST. LOUIS, March 2, 2021 /PRNewswire/ -- Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into…
